Evidence map›Paper›PMID 29318412›Full record

ReviewHeart failure reviews2018

Heart failure risk and major cardiovascular events in diabetes: an overview of within-group differences in non-insulin antidiabetic treatment.

Paola Terlizzese, Fabrizio Losurdo, Massimo Iacoviello, Nadia Aspromonte

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Paola TerlizzeseSchool of Cardiology, University of Bari, Bari, Italy.
Fabrizio LosurdoDiabetic Foot Care Center, Humanitas Gavazzeni, Bergamo, Italy.
Massimo IacovielloCardiology Unit, Cardiothoracic Department, Policlinic University Hospital, Bari, Italy.
Nadia AspromonteDepartment of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Agostino Gemelli Foundation, Rome, Italy. nadia.aspromonte@gmail.com.ORCID 0000-0002-0369-2052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, great attention is paid to cardiovascular impact of non-insulin glucose-lowering drugs, particularly in terms of major cardiovascular events and risk of heart failure. In this regard, a surprising diversity among different molecules within the same pharmacological class has been noticed, yielding to an intra-class discrepancy which has no analogous in other cardiovascular fields. The aim of this paper is to review the literature, giving an insight of the heterogeneous effects among groups and within group shown by oral antidiabetic drugs, with a special concern to fragile patients, such as those with or at risk of heart failure.

Indexed as

Diabetes Mellitus, Type 2Global HealthHeart FailureHumansHypoglycemic AgentsIncidencePrognosisHypoglycemic AgentsAlpha-glucosidase inhibitorsBiguanidesDiabetesGLP-1 agonistsHeart failureOral antidiabetic drugsSGLT-2 inhibitorsSulfonylureasThiazolidinediones

Identifiers

PMID29318412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.